Aclaris Therapeutics (ACRS) Liabilities from Discontinued Operations (2018 - 2023)

Aclaris Therapeutics' Liabilities from Discontinued Operations history runs 6 years deep, the most recent figure standing at 2202000.0 for Q4 2023.

• In Q4 2023, Liabilities from Discontinued Operations changed 0.0% year-over-year to 2202000.0; the TTM figure through Dec 2023 stood at 2202000.0 (changed 0.0% YoY), while the FY2023 annual figure was 2202000.0, changed 0.0% from the prior year.
• Liabilities from Discontinued Operations for Q4 2023 stood at 2202000.0, roughly flat from 2202000.0 in the prior quarter.
• The five-year high for Liabilities from Discontinued Operations was 14501000.0 in Q3 2019, with the low at 2198000.0 in Q3 2021.
• The 5-year median for Liabilities from Discontinued Operations is 2202000.0 (2021), against an average of 3228666.67.
• The sharpest annual moves came in 2019 and 2020: Liabilities from Discontinued Operations jumped 238.79% in 2019, then sank 77.24% in 2020.
• Aclaris Therapeutics' Liabilities from Discontinued Operations stood at 4157000.0 in 2019, then fell by 25.16% to 3111000.0 in 2020, then retreated by 29.22% to 2202000.0 in 2021, then changed by 0.0% to 2202000.0 in 2022, then changed by 0.0% to 2202000.0 in 2023.
• Business Quant data shows ACRS's Liabilities from Discontinued Operations at 2202000.0 in Q4 2023, 2202000.0 in Q3 2023, and 2202000.0 in Q2 2023.